Sage Therapeutics, Inc. (SAGE) Stock Rating Reaffirmed by Chardan Capital
Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “hold” rating reissued by stock analysts at Chardan Capital in a report issued on Wednesday.
Other equities analysts have also recently issued reports about the company. Stifel Nicolaus began coverage on Sage Therapeutics in a research note on Wednesday, August 9th. They set a “buy” rating and a $104.00 target price on the stock. Canaccord Genuity reduced their target price on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a research note on Tuesday. SunTrust Banks, Inc. reissued a “buy” rating and set a $82.00 target price (down from $95.00) on shares of Sage Therapeutics in a research note on Wednesday. Needham & Company LLC reduced their target price on Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, BidaskClub cut Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 28th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.08.
Shares of Sage Therapeutics (SAGE) opened at 70.37 on Wednesday. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80. The company’s 50 day moving average is $82.79 and its 200-day moving average is $74.97. The firm’s market cap is $2.63 billion.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same quarter in the previous year, the company posted ($1.08) earnings per share. Equities research analysts predict that Sage Therapeutics will post ($7.38) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Sage Therapeutics, Inc. (SAGE) Stock Rating Reaffirmed by Chardan Capital” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/13/sage-therapeutics-inc-sage-rating-reiterated-by-chardan-capital.html.
A number of hedge funds have recently modified their holdings of SAGE. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares during the period. Turner Investments LLC purchased a new stake in Sage Therapeutics in the second quarter worth $159,000. Dubuque Bank & Trust Co. purchased a new stake in Sage Therapeutics in the second quarter worth $167,000. Canada Pension Plan Investment Board purchased a new stake in Sage Therapeutics in the second quarter worth $175,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Sage Therapeutics in the first quarter worth $180,000.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.